Boron: An intriguing factor in retarding Alzheimer's progression
Ashmita Das1, Vikas Rajput1, Durlav Chowdhury1
1Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India.
Neurochemistry International
|November 8, 2024
Summary
Boron, a vital micronutrient, may protect brain health and combat Alzheimer's disease (AD) by influencing protein aggregation. Further research into boron's molecular role could reveal new AD treatment strategies.
Area of Science:
- Neuroscience
- Biochemistry
- Nutritional Science
Background:
- Alzheimer's disease (AD) is a leading cause of mortality, characterized by protein accumulation and cellular damage in the brain.
- The exact causes of AD are not fully understood, but genetic and environmental factors are implicated.
- Boron is an essential micronutrient with potential neuroprotective properties, though its specific brain functions are unclear.
Purpose of the Study:
- To elucidate the molecular role of boron in the brain.
- To examine boron's impact on neurodegenerative diseases, particularly Alzheimer's disease.
- To explore potential novel therapeutic approaches for AD based on boron's function.
Main Methods:
- This review synthesizes existing research on boron's effects on the brain.
- It examines the link between boron, protein aggregation, and neurodegeneration.
- Information on boron's impact on Alzheimer's disease etiology is analyzed.
Main Results:
- Boron is recognized as a vital micronutrient essential for plant growth.
- Prior studies suggest boron possesses neuroprotective qualities and is important for brain health.
- The precise molecular mechanisms of boron in the brain require further investigation.
Conclusions:
- Understanding boron's molecular role in the brain is crucial for comprehending Alzheimer's disease.
- Boron may offer a novel therapeutic avenue for treating neurodegenerative disorders like AD.
- Further research into boron's neuroprotective mechanisms could lead to new AD treatment strategies.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
Role of Neurotransmitters in Memory
446
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
446
Alcohols from Carbonyl Compounds: Reduction
10.2K
Reduction is a simple strategy to convert a carbonyl group to a hydroxyl group. The three major pathways to reduce carbonyls to alcohols are catalytic hydrogenation, hydride reduction, and borane reduction.
Catalytic hydrogenation is similar to the reduction of an alkene or alkyne by adding H2 across the pi bond in the presence of transition metal catalysts like Raney Ni, Pd–C, Pt, or Ru. Aldehydes and ketones can be reduced by this method, often under mild to moderate heat (25–100°C) and...
Catalytic hydrogenation is similar to the reduction of an alkene or alkyne by adding H2 across the pi bond in the presence of transition metal catalysts like Raney Ni, Pd–C, Pt, or Ru. Aldehydes and ketones can be reduced by this method, often under mild to moderate heat (25–100°C) and...
10.2K
The Blood-brain Barrier
46.8K
Overview
46.8K


